Oncology electric field treatment approved for listing in mainland China

BEIJING, May 14 (Xinhua Li Yanan) And Ding Pharmaceuticals and Novocure Company recently announced that China's State Drug Administration has approved the tumor electric field treatment of Epshield's listing application, for the treatment of newly diagnosed glioblastoma patients with tamoxamine, as well as as as a single therapy for the treatment of patients with recurrent glioblastomaGlioblastoma is the most common primary brain tumor, and Epshield is the first treatment approved for glioblastoma in mainland China in 15 yearsaccording to, cerebral glioma refers to the tumor originating in the glioblastoma cells of the brain, is the most common primary intracranial tumor, the World Health Organization (WHO) central nervous system tumor classification of glioma into I-IV grade, I, II for low-level glioma, III, IV level for high-level gliomaGlioblastoma (GBM) is the highest level and the highest degree of malignancy (IV) of gliomaglioblastoma (GBM) is the most common and invasive adult brain tumor, accounting for 56% of all gliomas and 15% of all primary brain tumorsAs the most common malignant tumor of the nervous system, the malignant degree of glioma is high, fast growth, short course, relapse and high disability after surgery, and is considered to be one of the most difficult difficult tumors in neurosurgery treatment"In China, more than 45,000 patients are diagnosed with glioblastoma each year, and treatment is very limited," said Jiang Tao, director of theBeijing Institute of Neurosurgery in, Beijing, and founder and founder of the China Glioma Genome Mapping Database (CGGA), beijing Tiantan HospitalAs the first new treatment in the field in more than a decade, Epshields has been included as a Level 1 piece of evidence in the Health and Reform Commission's first "Regulations for the Treatment of Gliomas( 2018 Edition)." It is very much expected to be the standard treatment for glioblastoma patients, giving hope to more patientsaccording to, tumor electric field therapy is a tumor treatment that uses specific electric field frequencies to interfere with cell division, inhibit tumor growth and cause the death of cancer cells affected by electric fieldEpshields has treated more than 15,000 glioblastoma patients worldwide by covering electric fields to specific areas to treat tumorstumor electric field treatment has also been approved by the U.SFood and Drug Administration for treatment of malignant pleural mesothelioma (MPM), an indication that will then be submitted in China In addition to glioblastoma and MPM, several key global Phase 3 clinical studies are being conducted to evaluate the efficacy of tumor electric field therapy for the treatment of brain metastasis, non-small cell lung cancer, pancreatic cancer and ovarian cancer, while Phase 2 clinical studies for liver and stomach cancer are also under way William Doyle, Executive Chairman of Novocure, said: "Through the continuous development and commercialization of this innovative technology for tumor electric field therapy, we hope to continue to extend the survival of patients with the most malignant types of tumors Greater China has the largest number of glioblastoma patients in the world, and Epshield's approval in this region is a further fulfillment of our commitment that tumor electric field treatment will benefit more patients by Bai Jiaxuan Source: